Abstract PL02-04: IDH mutations and tumorigenicity
| Autor: | Véronique Saada, Katharine E. Yen, Virginie Penard-Lacronique, Frank Salituro, Shinsan Su, Samuel V. Agresta, Marion Dorsch, Scott A. Biller, Jeremy Travins, Kim Straley, Wentao Wei, Erin Artin, David P. Schenkein, Cyril Quivoron, Shunqi Yan, Janeta Popovici-Muller, Yi Gao, Stefan Gross, Fang Wang, Andrew Kernytsky, Elena Mylonas, S. de Botton, Erica Hansen, Stefanie Schalm, Stuart Murray, Byron DeLaBarre, Wei Liu, Jeffrey O. Saunders, Camelia Gliser, Hua Yang, Lenny Dang |
|---|---|
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Molecular Cancer Therapeutics. 12:PL02-04 |
| ISSN: | 1538-8514 1535-7163 |
| Popis: | Mutations in the isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) genes are present in ∼20% of acute myeloid leukemia, and cause a neomorphic enzyme activity that results in the production of 2-hydroxyglutarate (2HG). Mutational and epigenetic profiling of a large patient cohort of acute myeloid leukemia (AML) has revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and impaired hematopoietic differentiation. To further investigate the intrinsic effect of 2HG on hematopoietic proliferation and differentiation, we transfected an erythroleukemia cell line (TF-1) with either IDH1 or IDH2 mutant alleles. These cells overexpress the mutant enzyme, have high levels of 2HG, and exhibit GM-CSF independent growth. Consistent with clinical observations, overexpression of the IDH mutant proteins led to hypermethylation of both histones and DNA. These results suggest that mutations in IDH1/2 could lead to epigenetic rewiring of cells that could facilitate the gain of function phenotype. We are currently studying the global and specific effects of IDH1/2 mutant overexpression to gain a broader understanding of the biological consequence of the IDH1/2 gain of function mutations. We have also generated mutation selective molecules that are capable of inhibiting IDHm enzymes. Upon compound treatment in vitro, we are able to reverse hypermethylation of both histones and DNA and induce cellular differentiation in IDHm cell lines and primary human IDHm AML patient samples(1, 2). These data suggest that an inhibitor of IDH1/2 mutations could correct the altered gene expression patterns seen in IDH1/2 mutant AML tumors leading to a profound effect on hematopoietic differentiation, proliferation and tumor growth. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):PL02-04. Citation Format: F. Wang, J. Travins, B. DeLaBarre, V. Penard-Lacronique, S. Schalm, E. Hansen, K. Straley, A. Kernytsky, W. Liu, C. Gliser, H. Yang, S. Gross, E. Artin, V Saada, E. Mylonas, C. Quivoron, J. Popovici-Muller, J. O. Saunders, F. G. Salituro, S. Yan, S. Murray, W. Wei, Y. Gao, L. Dang, M. Dorsch, S. Agresta, D. P. Schenkein, S. A. Biller, S. M. Su, S. de Botton, Katharine E. Yen. IDH mutations and tumorigenicity. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr PL02-04. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|